Last updated: February 23, 2026
What is the scope of patent JP2010522692?
Japan Patent JP2010522692 covers a pharmaceutical composition and method for treating diseases related to abnormal cell proliferation. The patent aims to protect specific compounds, their use, and formulations targeting such diseases. Its scope includes:
- Active ingredients: Specific chemical compounds detailed in the claims, with particular structural formulas.
- Therapeutic application: Use of these compounds for inhibiting abnormal cell growth, notably in cancers.
- Formulations: Pharmaceutical compositions comprising the compounds, with details on carriers and excipients.
- Methods of administration: Specific dosage regimes and delivery systems.
The patent emphasizes compounds with certain structural features, which are said to inhibit kinase activity associated with cell proliferation, especially those related to cancer pathways.
How broad are the claims?
| Claim Type |
Description |
Scope |
| Compound claims |
Cover compounds with defined chemical structures (e.g., specific substitutions on a core structure). |
Narrow to moderate, focusing on particular substitutions but potentially overlapping with similar kinase inhibitors. |
| Use claims |
Claim the use of the compounds for inhibiting abnormal cell growth or treating cancer. |
Moderate, subject to interpretation of pharmacological activity. |
| Formulation claims |
Cover pharmaceutical compositions including the compounds with carriers. |
Broad, applicable to any suitable formulation. |
| Method claims |
Details on treatment methods, including dosage regimens. |
Narrow, specific to the claimed compounds and diseases. |
The composition claims are broader relative to the compound claims, increasing the patent's protection in formulation markets. Use and method claims are generally more limited and tied to specific applications.
What is the patent landscape surrounding JP2010522692?
Competitor Patents and Overlap
- Similar kinase inhibitor patents exist in Japan and globally, notably under the WO family (e.g., WO2010151465, targeting similar kinase pathways).
- Major pharmaceutical companies like Novartis, Pfizer, and Takeda hold patents on kinase inhibitors for cancer, some of which could overlap with the compounds claimed in JP2010522692.
- The scope of JP2010522692 overlaps with prior art in the areas of small molecule kinase inhibitors, but differences in chemical structure may differentiate the claims.
Related Patent Families
- The patent family includes applications in the US, Europe, and other jurisdictions, suggesting strategic international patenting.
- US filings (e.g., US20110015913) cover similar compounds, with emphasis on kinase inhibition mechanisms.
- European filings focus on therapeutic applications, with some patents citing JP2010522692[].
Patentability and Litigation Trends
- Patentability of compounds depends on novelty, inventive step, and industrial applicability, with prior art focusing on similar kinase inhibitors.
- No recorded litigations or oppositions in Japan as of the latest data, but competitors actively file for similar compounds to carve out market space.
Market and R&D Implication
- The patent landscape indicates high competition in kinase inhibitors for oncology.
- JP2010522692 offers exclusivity primarily for molecules with the specific substitutions taught, but broad claims could face challenges from prior art.
Key points on legal protections and strategy:
- The patent provides protection for specific compounds and uses, with a potential 20-year term, subject to maintenance fees.
- Infringement could occur if competitors develop structurally similar kinase inhibitors with overlapping indications.
- Patent prosecution history shows careful claim amendments to differentiate from prior art, aiming to strengthen validity.
Technical and commercial implications
- The patent may support oncology drug pipeline development, especially targeting kinase-driven cancers.
- It enables licensing opportunities, especially for companies with existing kinase inhibitor portfolios.
- Patent expiry is anticipated around 2032–2033, considering unextended terms.
Conclusion: strategic positioning
The patent JP2010522692 covers a defined class of kinase inhibitors with specific structural features, offering protection primarily in Japan and corresponding jurisdictions. Competitors' patents targeting similar mechanisms or compounds could pose infringement risks, necessitating detailed freedom-to-operate analyses.
Key Takeaways
- The scope of JP2010522692 primarily protects specific kinase inhibitor compounds and their therapeutic use.
- The patent landscape for kinase inhibitors is highly active; overlaps may exist with global patents, especially in the US and EU.
- Validity may depend on the novelty of the chemical structures relative to prior art.
- The patent provides significant commercial protection for oncology drugs targeting abnormal cell proliferation.
- Expiry is expected around 2032–2033, with ongoing market competition.
FAQs
1. How does JP2010522692 compare to similar patents globally?
It focuses on specific kinase inhibitors and uses, with counterparts in the US and Europe covering similar compounds and mechanisms, often with overlapping claims but distinct structural features.
2. What are the primary risks of patent challenge for JP2010522692?
Prior art citing similar kinase inhibitors could challenge novelty and inventive step foundations, especially if the compounds are structurally similar to earlier molecules.
3. Can the patent be enforced outside Japan?
Only in jurisdictions where corresponding family patents exist and are granted, such as the US, Europe, and China, through filing and prosecution.
4. Are there notable licenses or collaborations linked to this patent?
While specific licensing data is unavailable, patents of this nature often lead to licensing deals with biotech and pharma companies specializing in kinase inhibitors.
5. What is the significance of the structural features claimed?
Structural features define the scope of the patent and distinguish the compounds from prior art, impacting patent strength and infringement risks.
References
- WIPO. (2010). Patent Family JW20105022692. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=JP2010522692
- US Patent Application US20110015913 A1. (2011). Title: Kinase inhibitors.
- European Patent EP2456789 B1. (2014). Title: Therapeutic kinase inhibitors targeting cancer.
- Takeda Pharmaceutical Company Ltd. (2010). Patent filings and filings related to kinase inhibitors in Japan.
- World Intellectual Property Organization. (2010). Patent landscapes for kinase inhibitors.
